{"id":"dhea-0-25","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaginal discharge"},{"rate":null,"effect":"Vaginal irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hot flashes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DHEA is an endogenous steroid hormone precursor that declines with age. When administered as a vaginal insert at 0.25% concentration, it is locally converted to estrogen and testosterone by tissue enzymes, providing hormone replacement therapy for menopausal symptoms without systemic hormone exposure. This localized approach aims to treat vaginal atrophy and related symptoms while minimizing systemic side effects associated with traditional hormone replacement therapy.","oneSentence":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:25.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women"},{"name":"Vaginal atrophy and related menopausal symptoms"}]},"trialDetails":[{"nctId":"NCT01846442","phase":"PHASE3","title":"Topical DHEA Against Vaginal Atrophy","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2007-06","conditions":"Vaginal Atrophy","enrollment":218},{"nctId":"NCT01256684","phase":"PHASE3","title":"DHEA Against Vaginal Atrophy - 3-Month Efficacy Study","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2010-12","conditions":"Vaginal Atrophy","enrollment":255},{"nctId":"NCT01358760","phase":"PHASE3","title":"Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2011-06","conditions":"Vaginal Atrophy","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prasterone, Dehydroepiandrosterone"],"phase":"phase_3","status":"active","brandName":"DHEA (0.25%)","genericName":"DHEA (0.25%)","companyName":"EndoCeutics Inc.","companyId":"endoceutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women. Used for Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women, Vaginal atrophy and related menopausal symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}